WHAT CLINICIANS NEED TO KNOW ABOUT ANTIVIRAL DRUGS AND VIRAL RESISTANCE

Richard L. Hodinka, PhD

During the last decade, significant advances have been made in the development and use of antiviral agents for the successful treatment of a number of viral infections. An expanding array of antiviral drugs are currently available for the management of infections caused by herpes simplex virus types 1 and 2 (HSV-1 and HSV-2), cytomegalovirus (CMV), varicella-zoster virus (VZV), influenza A virus, respiratory syncytial virus (RSV), human immunodeficiency virus type 1 (HIV-1), papillomaviruses, and hepatitis B and C viruses. The increased number and use of antiviral agents, however, has led to the emergence of drug-resistant viruses, particularly in immunocompromised patients such as those with acquired immunodeficiency syndrome (AIDS) or hematologic malignancy or those who have undergone organ transplantation. For comprehensive reviews on specific viruses, see references 26, 41, 64, 81-83, and 102.

Clinical situations that favor the development of resistance include long-term suppressive therapy, recurrent intermittent therapy, and the use of less than optimum doses of an antiviral agent. Generally, the emergence and isolation of drug-resistant viruses is associated more so with the therapeutic use of antiviral agents and does not seem to be caused by prophylactic treatment. As more patients fail to respond to appropriate therapy and additional antiviral agents are produced, it will also become important for diagnostic virology laboratories to provide...
rapid and practical antiviral susceptibility testing to assist physicians in defining drug resistance and choosing appropriate alternative therapies.

This review describes the major antiviral agents, their mechanisms of action, and the development of drug resistance following antiviral therapy. A brief overview of the available phenotypic and genotypic susceptibility assays for detecting antiviral resistance is also discussed.

MECHANISMS OF ANTIVIRAL DRUG ACTION AND VIRAL RESISTANCE

Herpesviruses

Human herpesviruses have a worldwide distribution and are a frequent cause of infections in immunocompetent and immunocompromised hosts. The number of severe and life-threatening conditions caused by these viruses is significant and includes localized oral, genital, and dermal infections, chickenpox, infectious mononucleosis, encephalitis, post-transplant lymphoproliferative disorder, and roseola infantum. There are a number of antiviral agents licensed for clinical use for the treatment and prophylaxis of herpesvirus infections (Table 1). Most are nucleoside analogs that require conversion to mono-, di-, and triphosphate forms by either cellular kinases, viral kinases, or both to selectively inhibit the replication of herpesviruses. This class includes vidarabine, acyclovir, valacyclovir, famciclovir, ganciclovir, cidofovir, idoxuridine, and trifluridine. A second class of antiviral drugs with action against herpesviruses is represented by the recently developed pyrophosphate analog foscarnet.

Vidarabine

Vidarabine (9-β-darabinofuranosyladenine; adenine arabinoside; araA; Vira-A) is an adenosine nucleoside analog with in vitro activity against HSV-1 and HSV-2, VZV, CMV, EBV, vaccinia virus, and hepatitis B virus and in vivo activity limited to HSV-1, HSV-2, and VZV.8, 51, 57 The drug is licensed for ophthalmic and intravenous use in the United States. Although the mechanism of action for vidarabine is unclear, the drug is phosphorylated by cellular kinases to its triphosphate form and prevents viral DNA synthesis through inhibition of the viral DNA polymerase. Vidarabine has efficacy for the treatment of herpes encephalitis, neonatal HSV infection, herpes keratitis, and mucocutaneous HSV infection and zoster in the immunocompromised host. The drug is not easy to use, however, because of its toxicity, poor solubility in water, and rapid deamination in vivo to a less active compound, arahypoxanthine. As such, vidarabine is seldom used and has been largely replaced by acyclovir. Resistance to vidarabine has not been identified in a clinical setting, although drug-resistant isolates can be induced in the laboratory and are caused by an altered viral DNA polymerase.22 Vidarabine has
### Table 1. AVAILABLE ANTIVIRAL AGENTS FOR HERPESVIRUSES: CLINICAL INDICATIONS AND MECHANISMS OF RESISTANCE

| Antiviral Agent       | Approved Clinical Indications                                                                 | Resistance Mechanisms                           |
|-----------------------|---------------------------------------------------------------------------------------------|--------------------------------------------------|
| **Nucleoside Analog** |                                                                                             |                                                  |
| Acyclovir             | Primary and recurrent herpes, HSV encephalitis, neonatal herpes, treatment and prophylaxis of mucocutaneous HSV infection, primary varicella or zoster in immunocompromised host | Altered or deficient viral thymidine kinase; altered DNA polymerase |
| Cidofovir             | CMV retinitis in patients with AIDS                                                          | Altered DNA polymerase                           |
| Famciclovir           | Recurrent genital HSV and zoster infections in adults                                         | Altered or deficient viral thymidine kinase; altered DNA polymerase |
| Ganciclovir           | Treatment of CMV in immunocompromised host, prophylaxis of transplant and HIV-infected patients | Diminished drug phosphorylation; altered DNA polymerase |
| Idoxuridine           | Herpes keratitis (topical use only)                                                          | Unknown                                          |
| Trifluridine          | Herpes keratitis (topical use only)                                                          | Unknown                                          |
| Valacyclovir          | Recurrent genital HSV and zoster infections in immunocompetent adults                         | Altered or deficient viral thymidine kinase; altered DNA polymerase |
| Vidarabine            | HSV encephalitis, neonatal herpes, herpes keratitis, zoster in immunocompromised host         | Altered DNA polymerase                           |
| **Pyrophosphate Analog** |                                                                                             |                                                  |
| Foscarnet             | Mucocutaneous acyclovir-resistant HSV infections, CMV retinitis                              | Altered DNA polymerase                           |

HSV = herpes simplex virus; CMV = cytomegalovirus.

In vitro activity against acyclovir-resistant HSV and VZV isolates, but the drug has not proven useful for the treatment of these isolates in HIV-infected patients.89

**Acyclovir**

Acyclovir (9-[2-hydroxyethoxymethyl] guanine; acycloguanosine; Zovirax) is a guanosine analog that has good in vitro activity against HSV-1, HSV-2, and VZV but limited activity against CMV, EBV, and human herpesvirus-6 (HHV-6).116 It is most useful clinically for the treatment of HSV and VZV infections. Acyclovir accumulates only in
cells infected with herpesviruses in which it is phosphorylated by a viral-specific thymidine kinase to its monophosphate form. It is further phosphorylated to the diphosphate and active triphosphate forms by cellular enzymes; the acyclovir triphosphate inhibits viral DNA polymerase by acting as an immediate DNA chain terminator. Acyclovir is efficacious for the treatment of primary and recurrent HSV and VZV infections, HSV encephalitis, neonatal herpes, and the management of mucocutaneous HSV infection. Resistance to acyclovir can result from mutations in the genes encoding the viral thymidine kinase (TK) or the viral DNA polymerase.\textsuperscript{23, 42, 53, 94} Mutations in the gene for TK can result in viral isolates that are either deficient (TK\textsuperscript{−}) in or have altered production (TK\textsuperscript{A}) of viral thymidine kinase activity.\textsuperscript{23, 34, 42, 50, 94} Viral isolates with a TK\textsuperscript{−} phenotype cause a decrease or lack of acyclovir phosphorylation, whereas TK\textsuperscript{A} strains result in altered substrate binding properties for acyclovir.

Valacyclovir

Valacyclovir (L-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl) methoxy] ethyl ester; Valtrex) is the L-valyl ester of acyclovir that has been recently licensed for treatment of recurrent genital HSV infections and herpes zoster in immunocompetent adults.\textsuperscript{1, 11} The drug is rapidly and extensively converted to acyclovir after oral administration, resulting in a 3 to 5 fold increase in the bioavailability of acyclovir over that observed for oral doses of acyclovir itself. To date, clinical resistance to valacyclovir and comparative susceptibilities of acyclovir-resistant clinical isolates to valacyclovir and acyclovir have not been reported. The expected mechanisms of viral resistance to valacyclovir, however, are likely to be the same as those for acyclovir.

Famciclovir

Famciclovir (2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol diacetate; Famvir) is a synthetic guanine derivative that is the orally administered prodrug of the antiviral compound penciclovir.\textsuperscript{17, 113} It has been approved for use in adults for the treatment of recurrent genital HSV and herpes zoster. It is rapidly and extensively absorbed following oral administration and is converted to its active triphosphate form of penciclovir by mechanisms that are similar to acyclovir. Like acyclovir, penciclovir has good in vitro activity against HSV and VZV and limited activity against EBV and CMV. Unlike acyclovir, penciclovir is not an obligate chain terminator but is an effective inhibitor of DNA chain elongation. Also, despite a less powerful inhibition of the viral DNA polymerase than acyclovir, famciclovir has a much higher oral bioavailability, and its active form is phosphorylated much more efficiently and has a significantly longer intracellular half-life in herpes-infected cells. This may ensure prolonged antiviral activity in virus-infected cells and may be responsible for the lower and more convenient dosage regimen
of famciclovir. Resistance to the active metabolite of famciclovir has been documented, but the mechanisms have not been fully elucidated. Acyclovir-resistant clinical isolates of HSV and VZV that are deficient in viral thymidine kinase are cross-resistant to penciclovir; penciclovir is active in vitro, however, against some acyclovir-resistant isolates of HSV and VZV with an altered thymidine kinase or DNA polymerase. Foscarnet-resistant HSV isolates seem to be susceptible to penciclovir in vitro.

Ganciclovir

Ganciclovir (9-[(1,3-dihydroxy-2-propoxy)methyl] guanine; DHPG; Cytovene) is another nucleoside analog of guanine with antiviral activity against all of the herpesviruses. It is unique, however, in that it is up to 100-fold more potent than acyclovir against CMV. Although the in vitro activity of ganciclovir is equal to acyclovir for the inhibition of HSV and VZV, its toxicity and lack of selectivity for viral enzymes has limited the clinical use of ganciclovir to the treatment and prophylaxis of serious CMV infections in immunocompromised patients. Ganciclovir is activated to its monophosphate form by a viral-specific thymidine kinase in HSV-infected cells and, in CMV-infected cells, by a phosphotransferase encoded by the UL97 gene of CMV. Conversion to the active triphosphate form of ganciclovir is accomplished by cellular kinases. Ganciclovir triphosphate inhibits viral DNA synthesis by competitive inhibition of viral DNA polymerases and by direct incorporation into viral DNA, thereby terminating viral DNA elongation. The mechanisms of resistance to ganciclovir in CMV include alterations in the gene encoding the viral DNA polymerase and mutations in the catalytic domain of the phosphotransferase gene leading to a deficiency in drug phosphorylation.

Cidofovir

Cidofovir ((S)-1-[3-hydroxy-2-(phosphonomethoxy) propyl] cytosine; HPMPC) is a novel monophosphate nucleotide analog that is a selective and potent inhibitor of CMV replication and has antiviral activity against other herpesviruses. It is licensed in the United States as an alternative to ganciclovir or foscarnet for the treatment and prophylaxis of CMV retinitis in patients with AIDS. Because it contains a phosphonate group, viral-specific enzymes are not required for initial phosphorylation. Unlike ganciclovir, cidofovir is phosphorylated by cellular enzymes to its active diphosphate form, which selectively inhibits the viral DNA polymerase. This may prove advantageous for the alternative treatment of herpesvirus resistance to nucleoside analogs caused by deficient or altered viral enzymes that are required for conversion of certain drugs to their monophosphate form. The active diphosphate form also has a long intracellular half-life, allowing for a more convenient dosage regimen than either ganciclovir or foscarnet. Ganciclovir
and foscarnet must be administered 2 or 3 times daily during initial treatment and once daily for maintenance, whereas cidofovir can be given once weekly for 2 weeks followed by once every other week. In vitro combinations of cidofovir with acyclovir, ganciclovir, foscarnet, and zidovudine have demonstrated additive or synergistic inhibition of several human CMV strains. Although viral resistance to cidofovir has been demonstrated in vitro, it has not been documented in patients treated with the drug.65

Idoxuridine and Trifluridine

Idoxuridine (5-ido-2'-deoxyuridine; IUdR) and trifluridine (5-trifluoromethyl-2'-deoxyuridine; trifluorothymidine; TFT; Viroptic) are two thymidine nucleoside analogs used for the topical treatment of ocular herpes simplex virus infections. These drugs represent some of the earliest antiviral compounds developed, and their use is limited because of toxicity and insufficient potency. Idoxuridine and trifluridine are phosphorylated to the monophosphate form by viral thymidine kinase in HSV-infected cells and to the triphosphate form by cellular enzymes. Disruption of viral replication is thought to be related to inhibition of the viral DNA polymerase, but the exact mechanism of action of these drugs is unknown. Currently, only trifluridine is licensed for use in the United States. It has activity against HSV-1, HSV-2, vaccinia virus, and some strains of adenovirus. Trifluridine is indicated for the topical treatment of primary keratoconjunctivitis and recurrent epithelial keratitis caused by HSV-1 and HSV-2 and has been used as a topical treatment for acyclovir-resistant chronic mucocutaneous genital HSV infections in HIV-infected patients. Viral resistance to idoxuridine and trifluridine has been demonstrated in vitro, but resistance following clinical use has not been reported. Resistant mutants are thought to possess deficient or altered thymidine kinase activity, although the mutants have not been extensively characterized. Isolates resistant to idoxuridine are cross-resistant to trifluridine.

Foscarnet

Foscarnet (trisodium phosphonoformate; Foscavir) is unlike the described nucleoside analogs for use against herpesviruses in that it is an organic analog of inorganic pyrophosphate. It has antiviral activity against HSV-1, HSV-2, CMV, VZV, EBV, HHV-6, hepatitis B virus, and HIV-1. Foscarnet exerts its inhibitory effect by acting at the pyrophosphate binding site on viral-specific DNA polymerases and reverse transcriptases. Phosphorylation by thymidine kinase or other kinases is not required for activation of foscarnet. Thus, acyclovir-resistant HSV isolates that are TK- or TKA mutants and CMV UL97 mutants resistant to ganciclovir may be sensitive to foscarnet. Resistance to foscarnet is caused by mutations in the viral DNA polymerase gene; acyclovir- or ganciclovir-resistant isolates with altered DNA polymerase activity
may be resistant to the drug. Foscarnet is indicated for the treatment of ganciclovir-resistant CMV retinitis in patients with AIDS and for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. Acyclovir-resistant VZV has also been successfully treated with foscarnet.

**Clinical Importance of Herpesvirus Resistance**

Resistance of clinical HSV isolates to acyclovir is a problem of growing concern, occurring at rates of 2% to 14% in the immunocompromised host following prolonged courses of continuous or intermittent suppressive therapy. Acyclovir-resistant strains of HSV have been recovered from patients with AIDS, bone marrow and solid organ transplant recipients, and patients receiving cancer chemotherapy. Children with agammaglobulinemia or severe combined immunodeficiency and a neonate with laryngeal herpes have also been identified with acyclovir-resistant HSV infections. In these patients, resistant HSV can be associated with chronic, progressive, debilitating disease that does not respond to antiviral treatment. Resistance to acyclovir, however, is usually not associated with more severe or prolonged HSV infection. Also, acyclovir-resistant isolates may become latent and cause recurrent disease. In some patients, recurrences are caused by drug-sensitive isolates after the successful treatment of infection with a resistant virus. Most acyclovir-resistant clinical isolates of HSV are TK- mutants, although TK^A and DNA polymerase mutants have also been reported.

The recovery of acyclovir-resistant clinical isolates of HSV from immunocompetent patients is rare. Acyclovir-resistant HSV isolates have been obtained from individuals before therapy and from otherwise healthy patients on chronic suppressive therapy for genital herpes, although long-term treatment does not seem to increase the risk for HSV resistance nor has a correlation been established between these isolates and the clinical outcome in immunocompetent hosts. A single report suggests recurrent acyclovir-resistant HSV infection in an immunocompetent individual that correlated with clinical failure of antiviral therapy. This virus possessed a TK^A phenotype and may have been acquired from an HIV-infected sexual contact who received long-term acyclovir therapy for recurrent genital herpes. Foscarnet has been employed successfully as an alternative antiviral agent for treating TK- or TK^A acyclovir-resistant HSV infections. However, in vivo resistance to this drug has also been documented. Foscarnet-resistant HSV isolates show absolute or borderline susceptibility to acyclovir, possibly indicating that acyclovir and foscarnet possess different binding sites on the viral DNA polymerase. High-dose oral or intravenous acyclovir, either alone or in combination with foscarnet, has been employed for the successful treatment of foscarnet-resistant HSV isolates. Alternative drugs, such as famciclovir, valacyclovir, cidofovir,
and trifluridine, also may be considered for the treatment of foscarnet-resistant HSV strains, although their use in treating such isolates requires further investigation. Clinical isolates resistant to both acyclovir and foscarnet have also been reported.

Why immunocompromised patients are at greater risk of acquiring drug-resistant HSV strains compared to hosts with normal immunity is still unclear. It has been suggested that an increased viral burden during infection of immunocompromised patients favors a larger gene pool for the emergence of viral mutations during the selective pressure of antiviral therapy. Also, clinical isolates of HSV may represent a heterogeneous population containing both susceptible and resistant viruses; drug-resistant strains may be preferentially selected during antiviral therapy.

Acyclovir is the preferred drug for the treatment of primary VZV infection or herpes zoster in immunocompromised hosts. However, acyclovir-resistant clinical isolates of VZV have been recovered from both adult and pediatric AIDS patients who presented with indolent and disseminated, atypical hyperkeratotic or nodular lesions following long-term therapy. Similar to acyclovir-resistant HSV isolates, most acyclovir-resistant clinical isolates of VZV have deficient or altered thymidine kinase activity. Several VZV isolates, however, have been reported to be resistant to both acyclovir and the alternative drug foscarnet. This is most likely caused by mutations in the viral DNA polymerase gene but may also be a result of combined mutations in the thymidine kinase and DNA polymerase genes.

Resistance of CMV to ganciclovir has been reported in immunocompromised patients, particularly patients with AIDS receiving long-term ganciclovir treatment for CMV retinitis. Three distinct scenarios have been described for the development of ganciclovir-resistant CMV in some patients, including infection with a resistant virus before ganciclovir treatment, infection with a susceptible virus that became resistant over the course of therapy, and infection initially by a susceptible virus with the emergence of a genetically distinct resistant virus during treatment. A prevalence rate of 8% has been reported for ganciclovir-resistant CMV among AIDS patients who received prolonged treatment with intravenous ganciclovir for CMV retinitis. Ganciclovir-resistant clinical isolates also have been recovered from bone marrow transplant recipients and a patient with chronic lymphocytic leukemia. Although foscarnet is the alternative therapy for ganciclovir-resistant CMV infections, clinical CMV isolates resistant to foscarnet alone or in combination with ganciclovir resistance have been described. More recently, double resistance to ganciclovir and foscarnet has been reported for four clinical isolates of CMV obtained from four different AIDS patients following multiple sequential and combined courses of treatment with either or both drugs. Each isolate represented a single CMV strain and ganciclovir resistance was

*References 4, 5, 15, 31–33, 37, 55, 58, 96, and 109.
caused by a mutation in the UL97 phosphotransferase gene, whereas mutations in the UL54 DNA polymerase gene were responsible for resistance to foscarnet.\textsuperscript{5}

**Human Immunodeficiency Virus**

A number of antiretroviral drugs have been approved for the treatment of HIV infection,\textsuperscript{27, 69} and they are divided into three main classes based on their mode of inhibition of viral replication (Table 2). The first class represents the nucleoside analogs that inhibit the viral RNA-dependent DNA polymerase (reverse transcriptase) of HIV. Included in this drug class are zidovudine (3'-azido-3'-deoxythymidine; AZT; Retrovir), didanosine (2',3'-dideoxyinosine; ddI; Videx), zalcitabine (dideoxyctydine; ddC; Hivid), stavudine (2', 3'-didehydro-2', 3'-dideoxythymidine; d4T; Zerit), and lamivudine (3'-thia-2', 3'-dideoxycytidine; 3TC; Epivir). A second class of reverse transcriptase inhibitors are represented by the non-nucleoside analogs nevirapine (dipyridodiazepinone; Viramune) and delavirdine (bis (heteroaryl)-piperazine; Rescriptor). The third class are protease inhibitors and include saquinavir (RO-31-8959; Invirase), ritonavir (ABT-538; Norvir), indinavir (MK-639; Crixivan), and nelfinavir (AG-1343; Viracept). Therapy with these antiretroviral agents, either alone or in combinations, may be beneficial to prolong survival, to reduce the incidence and severity of opportunistic infections in patients with advanced HIV disease, and to delay disease progression in asymptomatic HIV-infected patients.

**Nucleoside Analogs**

The nucleoside analogs are all dideoxynucleosides that are converted by cellular enzymes to their mono-, di-, and active triphosphate forms to interact with the substrate binding site to competitively inhibit the activity of the viral reverse transcriptase.\textsuperscript{3, 27, 69} The triphosphate form can also act as an alternate substrate that is incorporated into the growing DNA chain, leading to chain termination. The spectrum of activity of these drugs extends to viruses that depend on reverse transcriptase or similar enzymes and includes HIV, other retroviruses, and hepatitis B virus.

**Non-Nucleoside Analogs**

The non-nucleoside analogs target the same enzyme as the nucleoside analogs, but they interact with the enzyme in a different way and their antiviral activity does not require any intracellular conversion of the drugs.\textsuperscript{27, 29, 69} These compounds interact directly with the reverse transcriptase, acting noncompetitively at an allosteric, nonsubstrate binding site of the enzyme. The non-nucleoside reverse transcriptase inhibitors are highly selective and potent inhibitors of HIV-1 replication.
Table 2. AVAILABLE ANTIVIRAL AGENTS FOR HUMAN IMMUNODEFICIENCY VIRUS: CLINICAL INDICATIONS AND MECHANISMS OF RESISTANCE

| Antiviral Agent | Approved Clinical Indications                                                                 | Resistance Mechanisms       |
|-----------------|-----------------------------------------------------------------------------------------------|-----------------------------|
| Nucleoside Analog |                                                                                               |                             |
| Zidovudine (AZT) | Treatment of HIV infection, prevention of maternal-fetal HIV transmission                     | Altered viral reverse transcriptase |
| Didanosine (ddl) | Treatment of HIV infection, AZT intolerance or AZT treatment failure in HIV infection         |                             |
| Zalcitabine (ddC) | Intolerance or treatment failure with AZT and ddl, used as combination therapy with other antiretroviral agents |                             |
| Stavudine (d4T)  | Treatment of HIV infection after prolonged, prior AZT therapy                                |                             |
| Lamivudine (3TC) | Treatment of HIV infection in combination with AZT                                             |                             |
| Non-Nucleoside Analog |                                                                                           | Altered viral reverse transcriptase |
| Nevirapine      | Treatment of HIV infection in combination with nucleoside analogs                             |                             |
| Delavirdine     | Treatment of HIV infection in combination with nucleoside analogs                             |                             |
| Protease Inhibitors |                                                                                   | Altered viral protease       |
| Indinavir       | Treatment of HIV infections as a monotherapy or in combination with nucleoside analogs        |                             |
| Ritonavir       | Treatment of HIV infections as a monotherapy or in combination with nucleoside analogs        |                             |
| Saquinavir      | Treatment of HIV infections in combination with nucleoside analogs                           |                             |
| Nelfinavir      | Treatment of HIV infections in combination with nucleoside analogs                           |                             |

but are inactive against HIV-2 or other retroviruses. They are equally effective against AZT-sensitive or AZT-resistant isolates. Similar to the nucleoside analogs, they also have excellent oral bioavailability.

Protease Inhibitors

The protease inhibitors are a newly developed class of antiretroviral drugs that selectively inhibit the viral proteases of both HIV-1 and HIV-
The HIV protease cleaves the viral gag-pol polyprotein precursor into the gag proteins and the enzymes integrase and protease during virus assembly and maturation. The enzyme is required for viral infectivity. Inhibition of HIV protease activity, therefore, leads to the development of immature, noninfectious viral particles. Protease inhibitors act at a postintegration step of HIV replication and have the distinct advantage over reverse transcriptase inhibitors of blocking late stages of viral replication and, thereby, preventing the spread of HIV from cells already infected with the virus. The major disadvantages of the protease inhibitors are their low solubility in aqueous medium and poor oral bioavailability. However, the oral bioavailability and solubility of certain protease inhibitors have been significantly enhanced by appropriate chemical modifications to the drugs.

Resistance to Antiretroviral Drugs

The development of HIV resistance to various antiretroviral drugs has been well documented in patients receiving antiretroviral therapy. The number of original articles on this subject is extensive and the readers should refer to references 26, 28, 29, 82-84, and 102 for more comprehensive reviews of the literature. The emergence of HIV antiviral drug resistance is thought to be a function of the length of therapy, stage of disease or viral burden, and the high spontaneous mutation rate in the viral genome during active replication of the virus. Prolonged therapy and advancing disease increase the likelihood of developing viral resistance. In vitro and in vivo resistance to various antiretroviral drugs is caused by the accumulation of specific mutations in the coding regions of either the reverse transcriptase or the protease of the virus, leading to single amino acid substitutions in the viral protein targets. The extent of resistance seems to be correlated with the number of mutations, although individual mutations can be interactive, causing changes in the resistance or susceptibility of HIV isolates.

Long-term monotherapy with nucleoside analogs such as AZT, ddI, ddC, and d4T have led to the recovery of drug-resistant HIV isolates. Resistance seems to develop within 6 to 12 months of initial therapy for these drugs. Mutations in the reverse transcriptase gene at codons 41, 67, 70, 215, and 219 confer resistance to AZT. Individual mutations cause only low-level resistance, whereas four mutations are required for high-level resistance to AZT. High-level AZT resistance develops with time and has been associated with a more rapid clinical progression of disease while receiving therapy. Also, AZT-resistant virus has been transmitted by parenteral exposure to HIV-infected blood, sexual contact, and from mother to fetus. Similarly, mutations in the reverse transcriptase gene at codons 74 or 184 are associated with resistance to ddI and cross-resistance to ddC, whereas the change at codon 74 can also suppress the effect of the AZT resistance mutation at codon 215 and restore sensitivity of the isolate to AZT. Resistance to ddC also has been associated with mutations at codons 65, 69, 75, and 215, whereas cross-resistance to ddI
has been observed with mutations at codons 65 and 75. Additionally, point mutations at positions 50 and 75 are associated with resistance to d4T and those at positions 65 and 184 with resistance to 3TC. Under the selective pressure of AZT, cross-resistance to other antiretroviral agents is uncommon and confined only to nucleoside analogs with an azido group. Therefore, AZT-resistant viruses will remain susceptible to all other nucleoside analogs, the non-nucleoside analogs, and the protease inhibitors. Unlike the other nucleoside analogs, resistance to 3TC monotherapy develops within days or weeks because high levels of resistance are conferred by only a single mutation at codon 184. The same mutation at codon 184 also can reverse the effects of multiple AZT resistance mutations.

Rapid development of resistant virus is also observed in many patients treated with the non-nucleoside analogs. Resistance to these drugs occurs within days to weeks and is the result of any one of a number of possible mutations in the gene for the reverse transcriptase. The mutations occur around the site in which the non-nucleoside analogs bind and, as is the case for nevirapine, cluster at codons 98, 100, 103, 106, 108, 181, 188, and 190. Resistance to one of the non-nucleoside analogs usually confers complete cross-resistance to all members of the group. The mutation at codon 181 causes high-level nevirapine resistance and cross-resistance to most other non-nucleoside reverse transcriptase inhibitors, while suppressing the effect of AZT resistance mutations. Coresistance to AZT and nevirapine can develop. A mutation at codon 236 has been described for the resistance of HIV isolates to delavirdine, which also confers an increased susceptibility of the isolates to other non-nucleoside inhibitors. Because of the rapid development of viral resistance with the non-nucleoside analogs, the potential of these agents as monotherapy is limited and they are only being used in combination with other antiretroviral drugs.

Human immunodeficiency virus isolates resistant to protease inhibitors can be selected by laboratory passage in the presence of a given drug and in vivo. A number of mutations within the protease gene have been recognized that confer viral resistance to the protease inhibitors and include codons 8, 32, 46, 48, 82, 90, and 97. Cross-resistance to multiple protease inhibitors following resistance to a single protease inhibitor also has been described.

**Combination Therapy for Treatment of HIV Infection**

Because monotherapy with available antiretroviral agents has had limited success in the prolonged treatment of HIV infection and has led to the occurrence of drug-resistant viruses, the efficacy of combination therapy is now being studied. The ultimate goals of combination therapy are to more effectively inhibit viral replication and to reduce the viral burden to extremely low levels for as long as possible to preserve immune function, prevent the development of drug resistance, and interrupt progression of disease. With this in mind, certain combina-
tions of drugs may demonstrate additive or synergistic antiviral effects, such as that already being described in ongoing studies of nucleoside analogs with each other or with the non-nucleoside analogs or protease inhibitors. Also, the combined selection of antiretroviral drugs that act on different stages of viral replication and do not induce cross-resistance or create increased toxicity may be beneficial for the adequate management of HIV disease.

Respiratory Viruses

Respiratory viruses represent a heterogeneous group of agents that can infect the human respiratory tract and cause significant morbidity and mortality. Severe illness commonly occurs in infants, the elderly, the chronically ill, and the immunocompromised. The viruses that are a major cause of acute respiratory disease include influenza A and B viruses, respiratory syncytial virus, parainfluenza virus types 1, 2, and 3, adenoviruses, rhinoviruses, and respiratory coronaviruses. The treatment of infections with these viruses, however, is mostly supportive and the number of available antiviral drugs in use is limited. Oral amantadine or rimantadine has been employed for influenza A viral illness\(^1\) and aerosolized ribavirin\(^2\) has been used for RSV infections (see Table 3).

**Amantadine and Rimantadine**

Amantadine (1-adamantanamine hydrochloride; Symmetrel) and its alpha-methyl derivative rimantadine (Flumadine) are primary symmetrical amines that are inhibitory to the replication of influenza A virus from each of the three antigenic subtypes isolated from humans (i.e., H1N1, H2N2, H3N2); neither drug has sufficient activity against influenza B virus isolates\(^3\). Both drugs are licensed in the United States for the treatment and prophylaxis of influenza A virus, but rimantadine has fewer side effects and a longer half-life for easier once-a-day use. Administration of either drug within 48 hours after the onset of illness can reduce the severity and duration of influenza disease among healthy individuals. Their mechanisms of action are identical and involve interference with the function of the transmembrane domain of the viral M2 matrix protein, thereby inhibiting the uncoating of the virus. These drugs also have been shown to prevent virus assembly during later stages of viral replication. Amantadine-resistant and rimantadine-resistant influenza A isolates have been recovered from adult and pediatric patients undergoing therapy or prophylaxis during epidemics of influenza disease\(^4\). Resistance develops rapidly, occurring within 2 to 3 days of starting treatment. Viral resistance is caused by point mutations in the gene encoding the M2 protein\(^5\) and the resistant isolates are transmissible to close contacts and cause typical influenza illness\(^6\). Cross-resistance between amantadine and rimantadine has been reported and is complete. The role of alternative antiviral com-
pounds for the prevention or therapy of influenza A infection has not been fully defined.

Ribavirin

Ribavirin (1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide; Virazole) is a synthetic nucleoside analog resembling guanosine and inosine. The drug has a broad in vitro antiviral activity against many RNA and DNA viruses, including RSV, influenza A and B viruses, parainfluenza viruses, adenoviruses, herpesviruses, bunyaviruses, arenaviruses, reoviruses, and HIV-1.², ⁵² It is converted by cellular enzymes to its mono-, di-, and triphosphate forms; the mono- and triphosphate forms are active. Although its exact mechanism of action is unknown, it seems to interfere with the expression of viral mRNA and to inhibit viral protein synthesis. Ribavirin has reported clinical efficacy against RSV, influenza A and B, hantavirus, and Lassa fever virus infections but is only licensed in the United States for the aerosolized treatment of hospitalized infants and young children with severe lower respiratory tract infections caused by RSV. The expense and mode of therapy limits the use of this antiviral drug. Viral resistance to ribavirin following patient therapy has not been documented to date.

Hepatitis B and C Viruses and Human Papillomaviruses

Interferon-α

Interferons belong to a class of immunomodulators called cytokines that are small glycoproteins or peptides that function like hormones to regulate the immune system. They are also released by eukaryotic cells in response to viral infection and act on surrounding uninfected cells to render them more resistant to infection by various DNA and RNA viruses.⁸, ⁵⁷ Interferons bind to specific cell-surface receptors, are internalized by the cell, and induce cellular activities that prevent viral penetration or uncoating, synthesis, and expression of viral mRNA, viral protein synthesis, and viral assembly and release. There are three major classes of human interferons, including interferon-α, interferon-β, and interferon-γ. Only interferon-α has been approved for use in the treatment of certain viral infections (Table 3). Chronic liver disease caused by hepatitis B and C viruses and condyloma acuminatum caused by human papillomaviruses have been shown to respond to treatment with interferon-α. Also, interferon-α has antiretroviral activity against the replication of HIV by directly inhibiting virus assembly or release. The in vivo actions of interferon-α, its role as an antiviral agent, and how viruses avoid the effects of this drug is complex and is not yet completely understood.
### Table 3. AVAILABLE ANTIVIRAL AGENTS FOR MISCELLANEOUS VIRUSES: CLINICAL INDICATIONS AND MECHANISMS OF RESISTANCE

| Antiviral Agent | Approved Clinical Indications | Resistance Mechanisms |
|-----------------|-------------------------------|-----------------------|
| **Primary Symmetrical Amine** | Amantadine or Rimantidine | Treatment or prophylaxis of influenza A virus | Altered transmembrane domain of M2 protein |
| **Nucleoside Analog** | Ribavirin | Treatment of hospitalized infants and young children with severe respiratory syncytial virus infections | Unknown |
| **Cytokine** | Interferon-α-3 | Intralesional treatment of refractory or recurring external condylomata acuminata | Unknown |
| | Interferon-α-2a | Treatment of Kaposi's sarcoma, treatment of hairy cell leukemia | Unknown |
| | Interferon-α-2b | Treatment of hepatitis B or C chronic liver disease, treatment of external condylomata acuminata, treatment of Kaposi's sarcoma, treatment of hairy cell leukemia | Unknown |

### ANTIVIRAL SUSCEPTIBILITY TESTING

**Clinical Indications**

The described emergence of antiviral drug resistance has led to a definite need for in vitro antiviral susceptibility testing. Laboratory confirmation of drug resistance may predict treatment failure, define cross-resistance to other antiviral agents, and lead to the institution of the most appropriate alternative therapy. Clinical situations that warrant the use of antiviral susceptibility testing include failure of HSV or VZV lesions to resolve or the appearance of new lesions while on acyclovir therapy, progressive CMV disease during ganciclovir therapy, continuous shedding or transmission of influenza A virus during treatment or prophylaxis with amantadine or rimantadine, and progression of HIV disease as measured by increased HIV-1 RNA plasma levels or decreased CD4⁺ cell counts in patients during antiretroviral therapy. To this end, both phenotypic and genotypic antiviral susceptibility assays have been developed for the determination of viral drug resistance.
Phenotypic Assays

A number of phenotypic assays have been described for testing the susceptibility of viruses to antiviral agents. Generally, phenotypic antiviral susceptibility assays require isolation and passage of the virus in cell culture before testing begins. A standard inoculum of the virus is then used to infect cell cultures to which various concentrations of an antiviral agent are added. The activity of the antiviral agent against the replication of the virus is measured by one of many methods, including the inhibition of plaque formation or virus-induced cytopathic effect; a decrease in the production of viral antigens, enzyme activities, or total virus yield; a reduction in viral nucleic acid synthesis; or the inhibition of cell transformation. With each method, results are expressed as the drug concentration that causes a 50% inhibition (IC₅₀) in the growth of the virus. Phenotypic antiviral susceptibility assays have been developed and are currently in use for HSV, CMV, VZV, influenza A virus, and HIV-1. Such assays have proven to be accurate and reliable for the determination of antiviral resistance.

There are some important caveats to phenotypic antiviral susceptibility testing, however, as no standards exist, and many variables can influence the final result. Comparison of in vitro susceptibility data among different laboratories are valid only if the same assay, host cell, virus inoculum, and range of drug concentrations are used. The definition of a sensitive or resistant isolate may differ for each assay system and for different laboratories performing the same assay. Efforts to develop standardized consensus assays for HSV, CMV, and HIV-1 are currently in progress. With the exception of HSV, phenotypic antiviral susceptibility testing also can take many weeks to complete for slow-growing viruses, such as CMV, VZV, and HIV-1, and therefore may not be rapid enough to influence therapeutic decisions. The current goal for these viruses is to develop more rapid phenotypic assays. In vitro susceptibility results also may not always correlate with clinical response. HSV isolates resistant to acyclovir in vitro have responded to antiviral treatment with the drug and patients with isolates that remain susceptible to acyclovir in vitro have failed therapy. Furthermore, patients can possess a heterogeneous population of viral isolates with different in vitro susceptibilities to a given drug.

Genotypic Assays

Genotypic assays have been developed for the rapid detection of genetic mutations that confer viral drug resistance. These assays involve using the polymerase chain reaction (PCR) for amplification of specific viral genes and direct sequencing of the amplified products to identify alterations in the viral genome known to be associated with viral resistance to a given antiviral agent. Genotypic assays have been used to screen CMV isolates for the identification of mutations in the CMV UL97 phosphotransferase gene and the UL54 DNA polymerase
gene that confer resistance to ganciclovir and/or foscarnet.\textsuperscript{5, 100} Also, these assays have been employed for the detection of specific mutations in the HIV-1 reverse transcriptase and protease genes following treatment of patients with antiretroviral drugs.\textsuperscript{56} Site-directed mutagenesis can be used to produce a new recombinant virus possessing defined genetic mutations to demonstrate that the presence of a suspected drug-resistant mutation causes a change in drug susceptibility of the virus. Genotypic assays offer the distinct advantages over phenotypic assays of speed and efficiency in analyzing large numbers of viral isolates. However, these assays are cumbersome, technically demanding, and not routinely available in clinical laboratories. Also, current genotypic assays only detect known drug-resistant mutations and the results may be confounded by the presence of mutations that have no bearing on drug resistance. Phenotypic assays are still required to identify drug-resistant viruses with novel mutations for antiviral resistance.

\textit{Quantitative Monitoring of Viral Load}

The development of laboratory assays to quantitate the levels of virus in infected individuals may prove to be the most valuable laboratory tool to assess disease progression, monitor the impact of antiviral therapy, and predict treatment failure and the emergence of drug-resistant viruses. Molecular methods such as quantitative competitive PCR, reverse transcriptase–PCR, nucleic acid sequence–based amplification, and branched-chain technology are now commercially available for the accurate quantitation of viral nucleic acids of HIV-1, CMV, and hepatitis B and C viruses.\textsuperscript{18, 85, 110} Such tests may influence the choice of initial therapy and tailor treatment regimens to reduce the risk for viral mutation and subsequent viral resistance. Sustained decreases in patient viral load during treatment suggests an appropriate antiviral effect, whereas a return of viral load to pretreatment levels is indicative of drug failure and the possible need for alternative therapy.

\textbf{CONCLUSIONS}

The emergence of viruses that are resistant to antiviral drugs is of growing clinical concern. Failure of patients to respond to appropriate therapy is closely related to the development of viral resistance and the transmission of drug-resistant viruses from patient to patient has been documented. Although great advances have been made in the production of new and effective antiviral agents, viruses resistant to single and multiple drugs continue to appear under the selective pressure of prolonged treatment of viral infections in the immunocompromised host. Critical to the understanding of antiviral resistance and the appropriate therapeutic management of patients is an appreciation by clinicians and laboratory personnel of the magnitude and significance of the problem and the need to identify drug-resistant viral isolates and to
define the mechanisms of antiviral resistance. This information should prove invaluable for the prudent selection and administration of antiviral agents.

References

1. Acosta EP, Fletcher CV: Valacyclovir. Ann Pharmacother 31:185–191, 1997
2. American Academy of Pediatrics, Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 92:501–504, 1993
3. Arts EJ, Wainberg MA: Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother 40:527–540, 1996
4. Baldanti F, Boeckh M, Chou S, et al: Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J Acquir Imm Def Syndr Hum Retrovirol 12(Suppl 1):S1–S22, 1996
5. Baldanti F, Sarasini A, Silini E, et al: Four dually resistant human cytomegalovirus strains from AIDS patients: Single mutations in UL97 and UL54 open reading frames are responsible for ganciclovir- and foscarnet-specific resistance, respectively. Scand J Infect Dis Suppl 99:103–104, 1995
6. Balfour HH Jr, Benson C, Braun J, et al: Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 7:254–260, 1994
7. Bean B, Fletcher C, Englund J, et al: Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: Correlation of viral susceptibilities and plasma levels with response to therapy. Diagn Microbiol Infect Dis 7:199–204, 1987
8. Bean B: Antiviral therapy: Current concepts and practices. Clin Microbiol Rev 5:146–182, 1992
9. Belshe RB, Burk B, Newman F, et al: Resistance of influenza A virus to amantadine and rimantadine: Results of one decade of surveillance. J Infect Dis 159:430–435, 1989
10. Belshe RB, Smith MH, Hall CB, et al: Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J Virol 62:1508–1512, 1988
11. Beutner KR: Valacyclovir: A review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 28:281–290, 1995
12. Bevilaqua F, Marcello A, Toni M, et al: Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient. AIDS 4:967–969, 1991
13. Birch CJ, Tachedjian G, Doherty RR, et al: Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. J Infect Dis 162:731–734, 1990
14. Biron KK, Fyfe JA, Noblin JE, et al: Selection and preliminary characterization of acyclovir-resistant mutants of varicella zoster virus. Am J Med 73:383–386, 1982
15. Biron KK: Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents. Transplant Proc 23:162–167, 1991
16. Boivin G, Edelman CK, Pedneault L, et al: Phenotypic and genotypic characterization of acyclovir-resistant varicella-zoster viruses isolated from persons with AIDS. J Infect Dis 170:68–75, 1994
17. Boyd MR, Safrin S, Kern ER: Penciclovir: A review of its spectrum of activity, selectivity, and cross-resistance pattern. Antiviral Chem Chemother 4(Suppl 1):3–11, 1993
18. Caliendo AM: Methods, interpretation and applications of HIV-1 viral load measurements. Clin Microbiol Newsletter 19:1–8, 1997
19. Chatis PA, Miller CH, Schrager LE, et al: Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 320:297–300, 1989
20. Chou S, Erice A, Jordan MC, et al: Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 171:576-583, 1995
21. Chou S, Guentzel S, Michels KR, et al: Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 172:239-242, 1995.
22. Coen DM, Fleming HE Jr, Leslie IK, et al: Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus. J Virol 53:477-488, 1985
23. Coen DM, Schaffer PA: Two distinct loci conferring resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci USA 77:2265-2269, 1980
24. Collins P: Viral sensitivity following the introduction of acyclovir. Am J Med (Suppl 2A) 85:129-134, 1988
25. Crumpacker CS, Schnipper LE, Marlowe et al: Resistance to antiviral drugs of herpes simplex virus isolated from a patient treated with acyclovir. N Engl J Med 306:343-346, 1982
26. D'Aquila RT: HIV-1 drug resistance. Molecular pathogenesis and laboratory monitoring. Clin Lab Med 14:393-422, 1994
27. De Clercq E: Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 8:200-239, 1995
28. De Clercq E: HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol 47:155-169, 1994
29. De Clercq E: New developments in the chemotherapy of lentivirus (human immunodeficiency virus) infections: Sensitivity/resistance of HIV-1 to non-nucleoside HIV-1-specific inhibitors. Ann N Y Acad Sci 724:438-456, 1994
30. Degelau J, Somain SK, Cooper SL, et al: Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 152:390-392, 1992
31. Drew WL, Miner RC, Busch DF, et al: Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 163:716-719, 1991
32. Drobyski WR, Knox KK, Carrigan DR, et al: Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation 52:155-157, 1991
33. Dunn JP, MacCumber MW, Forman MS, et al: Viral sensitivity testing in patients with cytomegalovirus retinitis clinically resistant to foscarnet or ganciclovir. Am J Ophthalmol 119:587-596, 1995
34. Ellis MN, Keller PM, Frye JA, et al: Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity. Antimicrob Agents Chemother 31:1117-1125, 1987
35. Engel JP, Englund JA, Fletcher CV, et al: Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA 263:1662-1664, 1990
36. Englund JA, Zimmerman ME, Swierkosz EM: Herpes simplex virus resistant to acyclovir. A study in a tertiary care center. Ann Intern Med 112:416-422, 1990
37. Erice A, Chou S, Biron KK, et al: Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 320:289-293, 1989
38. Erlich KS, Jacobson MA, Koehler JE, et al: Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. Ann Intern Med 110:710-713, 1989
39. Erlich KS, Mills J, Chatis P, et al: Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 320:293-296, 1989
40. Faulds D, Heel RC: Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 39:597-638, 1990
41. Field AK, Biron KK: "The end of innocence" revisited: Resistance of herpesviruses to antiviral drugs. Clin Microbiol Rev 7:1-13, 1994
42. Field HJ, Darby G, Wildy P: Isolation and characterization of acyclovir-resistant mutants of herpes simplex virus. J Gen Virol 49:115-124, 1980
43. Fife KH, Crumpacker CS, Mertz GJ, et al: Recurrence and resistance patterns of
herpes simplex virus following cessation of ≥6 years of chronic suppression with acyclovir. J Infect Dis 169:1338–1341, 1994
44. Fillet AM, Visse B, Caumes E, et al: Foscarnet-resistant multidermatomal zoster in a patient with AIDS. Clin Infect Dis 21:1348–1349, 1995
45. Gateley A, Gander RM, Johnson PC, et al: Herpes simplex virus type 2 meningoencephalitis resistant to acyclovir in a patient with AIDS. J Infect Dis 161:711–715, 1990
46. Hammer SM, Kessler HA, Saag MS: Issues in combination antiretroviral therapy: A review. J Acquir Imm Def Syndr 7(Suppl 2):S24–S37, 1994.
47. Hayden FG, Belshe RB, Clover RD, et al: Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 321:1696–1702, 1989
48. Hayden FG, Hay AJ: Emergence and transmission of drug-resistant influenza A viruses. Curr Top Microbiol Immunol 176:119–130, 1992.
49. Hayden FG, Sperber SJ, Belshe RB, et al: Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 35:1741–1747, 1991
50. Hill EL, Hunter GA, Ellis MN: In vitro and in vivo characterization of herpes simplex virus clinical isolates recovered from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 35:2322–2328, 1991
51. Hirsch MS, Kaplan JC, D'Aquila RT: Antiviral agents. In Fields BN, Knipe DM, Howley PM, et al (eds): Fields Virology, ed 3. Philadelphia, Lippincott-Raven, 1996, pp 431–466
52. Hruska JF, Bernstein JM, Douglas RG Jr, et al: Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother 17:770–775, 1980
53. Hwang CBC, Ruffner KL, Coen DM: A point mutation within a distinct conserved region of the herpes simplex virus DNA polymerase gene confers drug resistance. J Virol 66:1774–1776, 1992
54. Jacobson MA, Berger TG, Fikrig S et al: Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 112:187–191, 1990
55. Jacobson MA, Drew WL, Feinberg J, et al: Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 163:1348–1351, 1991
56. Katzenstein DA: Viral phenotype and genotype as markers in clinical trials. J Acquir Imm Def Syndr Hum Retrovirol 10(Suppl 1):S25–S34, 1995
57. Keating MR: Antiviral agents. Mayo Clin Proc 67:160–178, 1992
58. Knox KK, Drobyski WR, Carrigan DR: Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient. Lancet 337:1292–1293, 1991
59. Kost RG, Hill EL, Tigges M, et al: Brief report: Recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 329:1777–1782, 1993
60. Lalezari JP, Drew WL, Glutzer E, et al: Treatment with intravenous (s)-l-[3-Hydroxy-2-(Phosphonylmethoxy)propyl]-cytosine of acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with AIDS. J Infect Dis 170:570–572, 1994
61. Lange JMA: Triple combinations: Present and future. J Acquir Imm Def Syndr Hum Retrovirol 10(Suppl 1):S77–S82, 1995
62. Larder BA, Darby G: Virus drug-resistance: mechanisms and consequences. Antiviral Res 4:1–42, 1984
63. Larder BA: Viral resistance and the selection of antiviral combinations. J Acquir Imm Def Syndr Hum Retrovirol 10(Suppl 1):S28–S33, 1995
64. Laufer DS, Starr SE: Resistance to antivirals. Pediatr Clin North Am 42:583–599, 1995
65. Lea AP, Bryson HM: Cidofovir. Drugs 52:225–230, 1996
66. Lehman SN, Douglas JM, Corey L, et al: Recurrent genital herpes and suppressive oral acyclovir therapy. Relation between clinical outcome and in-vitro drug sensitivity. Ann Intern Med 104:786–790, 1986
67. Leport C, Puget S, Pepin JM, et al: Cytomegalovirus resistant to foscarnet: clinicovirologic correlation in a patient with human immunodeficiency virus. J Infect Dis 168:1329–1330, 1993
68. Linne mann CCJ, Biron KK, Hoppenjans WG, et al: Emergence of acyclovir-resistant varicella zoster virus in an AIDS patient on prolonged acyclovir therapy. AIDS 4:577–579, 1990
ABOUT ANTVIRAL DRUGS AND VIRAL RESISTANCE

69. Lipsky JJ: Antiretroviral drugs for AIDS. Lancet 348:800–803, 1996
70. Ljungman P, Ellis MN, Hackman RC, et al: Acyclovir-resistant herpes simplex virus causing pneumonia after marrow transplantation. J Infect Dis 162:244–248, 1990
71. Lurain NS, Thompson KD, Holmes EW, et al: Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J Virol 66:7146–7152, 1992
72. Lurain NS, Thompson KD: Current methods for antiviral susceptibility testing. Clin Microbiol Newsletter 19:41–48, 1997
73. Lyall EGH, Oglivie MM, Smith NM, et al: Acyclovir resistant varicella zoster and HIV infection. Arch Dis Child 70:133–135, 1994
74. Mast EE, Harmon MW, Gravenstein S, et al: Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 134:988–997, 1991
75. McLaren C, Chen MS, Ghazzouli I, et al: Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir. Antimicrob Agents Chemother 28:740–744, 1985
76. Norris SA, Kessler HA, Fife KH: Severe, progressive herpetic whitlow caused by an acyclovir-resistant virus in a patient with AIDS. J Infect Dis 157:209–210, 1988
77. Nugier F, Colin JN, Aymard M, et al: Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 36:1–2, 1992
78. Nyquist AC, Rotbart HA, Cotton M, et al: Acyclovir-resistant neonatal herpes simplex virus infection of the larynx. J Pediatr 124:967–971, 1994
79. Pahwa S, Biron K, Lim W, et al: Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS. JAMA 260:2879–2882, 1988
80. Parris DS, Harrington JE: Herpes simplex virus variants resistant to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother 22:71–77, 1982
81. Reusser P: Herpesvirus resistance to antiviral drugs: A review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect 33:235–248, 1996
82. Richman DD: Clinical significance of drug resistance in human immunodeficiency virus. Clin Infect Dis 21(Suppl 2):S166–S169, 1995
83. Richman DD: HIV drug resistance. Annu Rev Pharmacol Toxicol 32:149–164, 1993
84. Roberts NA: Drug-resistance patterns of saquinavir and other HIV protease inhibitors. AIDS 9(Suppl 2):S27–S32, 1995
85. Saag MS, Holodniy M, Kuritzkes DR, et al: HIV viral load markers in clinical practice. Nature Med 2:625–629, 1996
86. Sacks SL, Wanklin RJ, Reece DE, et al: Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity? Ann Intern Med 111:893–899, 1989
87. Safrin S, Assaykeen T, Follansbee S, et al: Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. J Infect Dis 161:1078–1084, 1990
88. Safrin S, Berger TG, Gilson I, et al: Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella zoster virus infection. Ann Intern Med 115:19–21, 1991
89. Safrin S, Crumpacker C, Chatis P, et al: A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. N Engl J Med 325:551–555, 1991
90. Safrin S, Kemmerly S, Plotkin B, et al: Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 169:193–196, 1994
91. Safrin S, Phan L: In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus. Antimicrob Agents Chemother 36:2747–2757, 1992
92. Safrin S: Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS. J Acquir Immune Defic Syndr 5(Suppl 1):S29–S32, 1992
93. Sarasini A, Baldanti F, Furione M, et al: Double resistance to ganciclovir and foscarnet of four human cytomegalovirus strains recovered from AIDS patients. J Med Virol 47:237–244, 1995
94. Schnipper LE, Crumpacker CS: Resistance of herpes simplex virus to acycloguanosine: Role of viral thymidine kinase and DNA polymerase loci. Proc Natl Acad Sci USA 77:2270-2273, 1980

95. Sibrack CD, Gutman LT, Wilfert CM, et al: Pathogenicity of acyclovir-resistant herpes simplex type 1 from an immunodeficient child. J Infect Dis 146:673–682, 1982

96. Slavin MA, Bindra RR, Gleaves CA, et al: Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 37:1360–1363, 1993

97. Smith KJ, Davis C, James WD, et al: Acyclovir-resistant varicella zoster responsive to foscarnet. Arch Dermatol 127:1069–1070, 1991

98. Snoeck R, Andrei G, Gerard M, et al: Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (s)-1-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis 18: 570–578, 1994

99. Snoeck R, Gerard M, Sadzot-Delvaux C, et al: Meningoradiculoneuritis due to acyclovir-resistant varicella-zoster virus in a patient with AIDS. J Infect Dis 168:1330–1331, 1993

100. Spector SA, Hsia K, Wolf D, et al: Molecular detection of human cytomegalovirus and determination of genotypic ganciclovir resistance in clinical specimens. Clin Infect Dis 21(Suppl 2):S170–S173, 1995

101. Stanat SC, Reardon JE, Erice A, et al: Ganciclovir-resistant cytomegalovirus clinical isolates: Mode of resistance to ganciclovir. Antimicrob Agents Chemother 35:2191–2197, 1991

102. Strair RK, Mellors JW: Resistance of human immunodeficiency virus-1 to antiretroviral drugs. AIDS Updates 6:1–4, 1993

103. Straus SE, Takiff HE, Seidlin M, et al: Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir. N Engl J Med 310:1545–1550, 1984

104. Sullivan V, Coen DM: Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs. J Infect Dis 164:781–784, 1991

105. Sullivan V, Talarico CL, Stanat SC, et al: A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162–164, 1992

106. Swierkosz EM, Biron KK: Antiviral agents and susceptibility testing. In Murray PR, Baron EJ, Pfister MA, et al (eds): Manual of Clinical Microbiology, ed 6. Washington, DC, ASM Press, 1995, p 1415–1423

107. Talarico CL, Phelps WC, Biron KK: Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS. J Virol 67:1024–1033, 1993

108. Tatarowicz WA, Lurain NS, Thompson KD: A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J Infect Dis 166:904–907, 1992

109. Tokumoto JIN, Hollander H: Cytomegalovirus polyradiculopathy caused by a ganciclovir-resistant strain. Clin Infect Dis 17:854–856, 1993

110. Urdea MS: Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV, and HIV. Clin Chem 39:725–726, 1993

111. Van Voris LP, Newell PM: Antivirals for the chemoprophylaxis and treatment of influenza. Semin Resp Infect 7:61–70, 1992

112. Verdonck LF, Cornelissen JJ, Smit J, et al: Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic BMT. Bone Marrow Transplant 11:177–179, 1993

113. Vere Hodge RA: Famciclovir and penciclovir. The mode of action of famciclovir including its conversion to penciclovir. Antiviral Chem Chemother 4:67–84, 1993

114. Wade JC, McLaren C, Meyers JD: Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 148:1077–1082, 1983

115. Wagstaff AJ, Bryson HM: Foscarnet. A reappraisal of its antiviral activity, pharmaco-
kinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48:199–226, 1994

116. Whitley RJ, Gnann JW Jr: Acyclovir: a decade later. N Engl J Med 327:782–789, 1992

117. Wolf DG, Smith IL, Lee DJ, et al: Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J Clin Invest 95:257–263, 1995

118. Youle MM, Hawkins DA, Shanson DC, et al: Acyclovir-resistant herpes in AIDS treated with foscarnet. Lancet ii:341–342, 1988

Address reprint requests to
Richard L. Hodinka, PhD
Clinical Virology Laboratory, Room 5140
Children's Hospital of Philadelphia
34th and Civic Center Boulevard
Philadelphia, PA 19104